The major indices dipped on global news and data, but we see resilience.
The stock is approaching its 200-day moving average.
With the stock close to a crucial support level, the position's risk/reward is significantly diminished.
We would not be surprised if it sold its Japan unit.
We will continue to build out the Celgene position on weakness.
A key drug meets a regulatory obstacle in the U.K., but we still see growth ahead.
We don't see it changing the stock's fundamentals, and in fact it could spur demand.
As the sector index turns south with other laggards, including the banks, the odds for an intermediate top are rising rapidly.
We want to spread our puts in order to lower the break-even on the trade.
We're bulking up on National Oilwell Varco, Express Scripts and Celgene on this pullback -- and taking profits in Nike and Macy's.